Search Results 591-600 of 17378 for Oncogene
Participation eligibility · Phase 2 Cohorts 1-4: an additional validated oncogenic driver that could cause resistance to LOXO-292 treatment. · Cohorts 1-5: prior ...
Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.
Learn about the types of tumors that make up this group of rare cancers. Find out about symptoms, causes, diagnosis and treatments.
This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with ...
... oncogenic-driver co-mutation with PI3K/AKT/PTEN alteration * Clinically significant abnormalities of glucose metabolism * Active brain metastases or ...
About this study. The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, ...
Josep M. Domingo Domenech, M.D., Ph.D., studies the molecular and cellular pathogenesis of prostate and bladder cancers.
In the first study, published in the journal PLoS Genetics, researchers studied variations across the genomes of 14,351 BRCA1 mutation carriers and found two ...
Mayo Clinic Comprehensive Cancer Center has four NCI SPORE grants: Breast cancer, hepatobiliary cancer, multiple myeloma and ovarian cancer.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.